Literature DB >> 23633449

Breast cancer genomics: challenges in interpretation and application.

Cathy M Kelly1, W Fraser Symmans, Eleni Andreopoulou, Giampaolo Bianchini.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23633449      PMCID： PMC3639537          DOI： 10.1634/theoncologist.2013-0116

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  8 in total

1.  Impact of multigene assays in early stage breast cancer.

Authors:  Shelly S Lo; Kathy S Albain
Journal:  Oncologist       Date:  2011-10-20

Review 2.  Gene-expression signatures in breast cancer.

Authors:  Christos Sotiriou; Lajos Pusztai
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

3.  The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.

Authors:  Jennifer E Joh; Nicole N Esposito; John V Kiluk; Christine Laronga; M Catherine Lee; Loretta Loftus; Hatem Soliman; Judy C Boughey; Carol Reynolds; Thomas J Lawton; Peter I Acs; Lucio Gordan; Geza Acs
Journal:  Oncologist       Date:  2011-10-20

4.  A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.

Authors:  Torsten O Nielsen; Joel S Parker; Samuel Leung; David Voduc; Mark Ebbert; Tammi Vickery; Sherri R Davies; Jacqueline Snider; Inge J Stijleman; Jerry Reed; Maggie C U Cheang; Elaine R Mardis; Charles M Perou; Philip S Bernard; Matthew J Ellis
Journal:  Clin Cancer Res       Date:  2010-09-13       Impact factor: 12.531

5.  Genomic index of sensitivity to endocrine therapy for breast cancer.

Authors:  W Fraser Symmans; Christos Hatzis; Christos Sotiriou; Fabrice Andre; Florentia Peintinger; Peter Regitnig; Guenter Daxenbichler; Christine Desmedt; Julien Domont; Christian Marth; Suzette Delaloge; Thomas Bauernhofer; Vicente Valero; Daniel J Booser; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

6.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Authors:  Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes
Journal:  Lancet Oncol       Date:  2009-12-10       Impact factor: 41.316

Review 7.  Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

Authors:  Kathy S Albain; Soonmyung Paik; Laura van't Veer
Journal:  Breast       Date:  2009-10       Impact factor: 4.380

8.  Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.

Authors:  Mitch Dowsett; Jack Cuzick; Christopher Wale; John Forbes; Elizabeth A Mallon; Janine Salter; Emma Quinn; Anita Dunbier; Michael Baum; Aman Buzdar; Anthony Howell; Roberto Bugarini; Frederick L Baehner; Steven Shak
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544
  8 in total
  1 in total

1.  Interpreting cancer biology: refining our therapeutic algorithm in breast cancer.

Authors:  Gabriel Hortobágyi; Pierfranco Conte
Journal:  Oncologist       Date:  2013
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.